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Abstract Genetic alterations can determine the natural
history of cancer and its treatment response. With further
advances in DNA sequencing technology, multiple novel
genetic alterations will be discovered which could be
exploited as prognostic, predictive and pharmacodynamic
biomarkers in the development and use of cancer thera-
peutics. As such, the importance in clinical practice of
efficient and robust somatic mutation testing in solid
tumours cannot be overemphasized in the current era of
personalized medicine. However, significant challenges
remain regarding the testing of genetic biomarkers in
clinical practice. Reliance on archived formalin fixed,
paraffin embedded tumour, obtained from diagnostic
biopsies, for testing somatic genetic alterations could
restrict the scientific community in asking relevant ques-
tions about a patient’s cancer biology. Problems inherent
with using formalin fixed, archival tissue are well recog-
nized and difficult to resolve. It could be argued that to
achieve rapid and efficient incorporation of genetic
biomarkers into clinical practice, somatic mutation testing
in cancer patients should be simpler, less invasive using
a readily available clinical sample, whilst maintaining
robustness and reproducibility. In this regard, use of cir-
culating free DNA (cfDNA) from plasma or serum as an
alternative and/or additional source of DNA to test cancer
specific genetic alterations is an attractive proposition. In
light of encouraging results from recent studies, this mini
review will discuss the current role and future potential of
somatic mutation testing from circulating or cell free DNA
derived from the blood of patients with solid tumours.
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Introduction
Genetic alterations that activate proto-oncogenes or inac-
tivate tumour suppressor genes are key steps in the pro-
gression of normal tissue to malignancy (Kopnin 2000). In
familial cancer syndromes, germline mutations predispose
to malignant transformation and often result in earlier onset
disease (Gatalica and Torlakovic 2008; Sluiter and van
Rensburg 2011). In contrast, in more common sporadic
cancers, the tumour usually originates from clonal expan-
sion of a transformed cell through the accumulation of
serial somatic mutations (Stratton et al. 2009). Currently,
approximately 400 cancer related genes have been identi-
fied (http://www.sanger.ac.uk/genetics/CGP/Census). With
recent advances in DNA sequencing technology, it is
envisaged that multiple novel somatic genetic alterations
will be discovered. These novel genetic variants may
provide important biomarker information to aid prediction
of the natural history of cancer or treatment response. In an
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era of targeted therapeutics, it is inevitable that testing the
molecular characteristics of patients’ tumours will be nec-
essary before recruitment into clinical trials to achieve the
ultimate goal of personalized medicine. Already, KRAS
mutation status is routinely determined in tumours of
patients with metastatic colorectal cancer and only those
patients with wild type KRAS are offered cetuximab, a
monoclonal antibody to EGFR receptor. As most biomarkers
predictive for treatment response are genetic biomarkers, the
importance of efficient and standardized testing for somatic
mutations is vital. However, currently significant challenges
remain in testing genetic biomarkers in clinical practice.
Firstly, tumour tissue is not always available for geno-
typing. For example, diagnosis in a significant number of
patients with lung cancer is based purely on cytology and as a
result there will be insufficient material available for com-
prehensive molecular profiling (Sequist et al. 2009). This
imposes immense difficulties if patients need to be selected
or stratified by mutation status before entering into clinical
trials or for routine clinical treatment with new biological
targeted agents. Secondly, even if biopsy material is avail-
able, the quality and quantity of tumour tissue is often vari-
able. Archived formalin fixed, paraffin embedded (FFPE)
tumour acquired for diagnosis usually contains a small
amount of tumour mixed with stroma, moreover and DNA is
usually degraded by formalin fixation (Plesec and Hunt
2009). Thirdly, logistical problems around retrieving
patients’ archival FFPE tumour blocks are also substantial.
Within large clinical trials, samples have to be retrieved from
many study sites and across different countries which is
costly and often slow. As an illustration of this problem, four
large studies of erlotinib and gefitinib in non-small cell lung
cancer (NSCLC) have reported molecular analysis but data
was derived from\30% of the patients enrolled (Riely et al.
2006). To achieve rapid and efficient incorporation of
genetic biomarkers into clinical practice, somatic mutation
testing in cancer patients should be simpler, less invasive
from a readily available clinical sample with maintained
robustness and reproducibility. In this regard, the use of
circulating free DNA (cfDNA) from plasma or serum as an
alternative source of DNA to test cancer specific genetic
alterations rather than being reliant on archival tumour
biopsy is an attractive proposition. In light of encouraging
results from recent studies, this mini review will discuss the
current role and future potential of somatic mutation testing
from circulating or cell free DNA (cfDNA) derived from the
blood of patients with solid tumours.
Circulating free DNA (cfDNA) and its potential
Circulating nucleic acids in humans were first described in
1948 by Mandel and Metais (1948). Characterization of
these nucleic acids in later studies revealed that they are
predominantly double stranded DNAs, circulating in
complexes with histones as mono or oligonuleosomes
(Stroun et al. 1987; Rumore and Steinman 1990). Low
levels of cfDNA can be detected in healthy individuals but
increased levels can be found in patients with a number of
diseases including patients with cancers (Leon et al. 1977).
Four decades after Mandel and Metais’s seminal discovery,
it was shown that tumour specific molecular characteristics
could be tested using cfDNA isolated from the plasma of
cancer patients (Stroun et al. 1987, 1989) providing a
potential source of tumour specific information that could
be utilized for cancer diagnosis, personalized medicine and
cancer prognosis. However, and perhaps surprisingly, the
mechanism and source of cfDNA release remains largely
uncertain. It has been suggested that cfDNA originates
from either malignant or haemopoietic apoptotic and
necrotic cells, from the lysis of circulating tumour cells or
from active secretion of nucleic acids by tumour cells
(Stroun et al. 2000, 2001). The detection of tumour specific
DNA alterations such as mutations and methylation in
cfDNA confirm that, at least in part, cfDNA is tumour
derived and provides a less invasive, more easily accessible
source of DNA for genetic analysis than tumour biopsies.
This is of increasing clinical importance in cancer medicine
with development of targeted agents, the benefit of which
is often determined by the presence or absence of genetic
mutations within the tumour cells (Van Cutsem et al. 2009;
Mok et al. 2009).
Recent advances in PCR based technology have now
allowed the analysis of point mutations in EGFR, KRAS,
BRAF and PIK3CA genes from cfDNA isolated from
patients’ plasma or serum (Kimura et al. 2007; Hodgson
et al. 2010; Board et al. 2009, 2010). These genes are of
particular importance in determining response to a variety
of novel agents in clinical use and in development for the
treatment of cancer. The optimal methodology for cfDNA
isolation and mutation detection is still unclear with a
variety of different techniques and technologies used in the
literature. However, combined with recent progress made
in this research field and further advances in technology,
somatic mutation testing from cfDNA has huge future
potential from a cancer therapeutic perspective.
As a biopsy is usually taken from one small part of the
tumour, it is debatable whether it represents the whole
tumour (Fleischhacker and Schmidt 2008). It has been
argued that analysis of cfDNA, on the other hand, might
yield information about all subclones within the tumour
(Fig. 1; Fleischhacker and Schmidt 2008). Moreover, real
time monitoring of the evolution of a tumour is desirable
for understanding of genotypic changes that are responsible
for cancer recurrence, progression and development of
drug resistance. In routine clinical practice, performing
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serial tumour biopsies is seldom practical or justified and to
achieve real time monitoring of tumour dynamics, muta-
tion testing should be minimally invasive and easily
repeatable. Blood based somatic mutation testing could
potentially meet these requirements. It could also be
envisaged that, to prove the mechanism of a drug targeted
towards a particular clone of mutant tumour cells, it would
be needed to demonstrate that these mutant cells are
eradicated after treatment. If a particular tumour derived
mutation(s) can be tested from circulating free DNA, dis-
appearance of these mutations from the circulation may
confirm that the drug is hitting its intended target. Fur-
thermore, reappearance of these mutations in the blood
stream may herald disease recurrence or drug resistance.
Lastly, whole genome profiling of cfDNA by next gener-
ation sequencing might lead to discovery of novel driver
mutations in cancer candidate genes and could significantly
advance our understanding of tumour biology.
Current status of somatic mutation testing from cfDNA
in cancer
Currently there is no routinely used blood based test for
somatic mutation detection in patients with solid tumours.
Wide variations in methodologies in analyzing cancer
specific mutations in cfDNA in the published studies
indicate that reproducibility remains a major issue and
technology platforms still need improvement. Standardi-
zation of techniques will be necessary before this alterna-
tive approach of somatic mutation testing could be
incorporated effectively into clinical trials and routine
clinical practice.
Lung cancer
Mutation in EGFR occurs in *35% of NSCLC patients of
East Asian origin and *16% in Western populations (Mok
et al. 2009; Rosell et al. 2009). Multiple in-frame deletions
in exon 19 and the p.L858R missense mutation in exon 21
comprise 90% of the mutations detected (Kosaka et al.
2004). Studies have confirmed EGFR mutations as a pre-
dictive biomarker of treatment response to tyrosine kinase
inhibitors, gefitinib and erlotinib (Yang et al. 2008; Sequist
et al. 2008; Inoue et al. 2006; Tsao et al. 2005). As such
screening for EFGR mutations in NSCLC patients is
deemed necessary before offering these drugs to patients.
However, NSCLC is frequently inaccessible to tumour
biopsy and diagnosis is often based on cytology or fine
needle aspirations, from which sufficient DNA for muta-
tion analysis can rarely be obtained. Previous studies
investigating mutation status of NSCLC demonstrated that
significant proportion of patients will have unknown
mutation status because tumour biopsy material is not
available or insufficient for genotyping (Riely et al. 2006;
Jackman et al. 2009). For this reason cfDNA from patients
with NSCLC offers a useful alternative for mutation
detection where tumour data is unavailable. Kimura et al.
(2006) first reported the feasibility of detection of EGFR
mutations in cfDNA extracted from serum of patients with
NSCLC. Two years later, the same group published results
from EGFR mutation analysis of 42 paired tumour and
serum samples (Kimura et al. 2007) using allele-specific
amplification refractory mutation testing system combined
with scorpion probes (Scorpion-ARMS). It was demon-
strated that EGFR mutation status was consistent in 39
(93%) of the 42 paired samples tested. However, this
Fig. 1 Harvesting tumour
derived DNA. Circulating free
DNA could represent genetic
profile of the tumour better than
DNA from biopsy. A primary
tumour could contain many
subclones of tumour cells,
which have different genetic
profiles, and as biopsy material
is usually obtained from only
one small part of the tumour, it
might not contain materials
from all the subclones (adapted
from Fleishhacker et al. 2008)
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encouraging result was not confirmed in another study
conducted by Maheswaran et al., which reported EGFR
mutations in only 33% of plasma-derived cfDNA samples
from 12 patients whose tumour was positive for EGFR
mutation by using Scorpion-ARMS (Maheswaran et al.
2008). More recently, the Spanish Lung Cancer Group
reported that of 164 patients with EGFR mutations in
tumours, 97 (59%) had an EGFR mutation in serum tested
by protein nucleic acids mediated PCR analysis (Rosell
et al. 2009). Almost all of the patients who initially
responded to gefitinib and erlotinib will eventually develop
resistance to the drugs. Development of a secondary EGFR
mutation, p.T790M, which inhibits binding of these drugs
to the ATP binding pocket of EGFR, accounts for acquired
resistance to EGFR targeted treatment in 50% of patients
(Engelman and Ja¨nne 2008). Kuang et al. demonstrated
that p.T790M mutation can be tested from plasma derived
cfDNA highlighting the potential role of mutation testing
from cfDNA in monitoring secondary resistance to anti-
cancer treatment (Kuang et al. 2009).
As KRAS mutations are also negative predictors of
response to anti-EGFR treatment in lung cancer, recent
studies also explored KRAS mutation testing from cfDNA
(Ramirez et al. 2003; Wang et al. 2010). Wang et al. (2010)
reported their findings from KRAS mutation analysis of
DNA extracted from 273 plasma samples and matched
tumour tissues from advanced NSCLC patients of East
Asian origin. PCR-restriction fragment length polymor-
phism (PCR–RFLP) combined with denaturing high per-
formance liquid chromatography was used for mutational
analysis. KRAS mutation was found in 35 (13%) plasma
samples and 30 (11%) tumours. Concordance of mutations
between plasma and tumour was 77%. The fact that more
mutations were found in plasma compared to tumour raises
the possibility of false positive results in plasma samples
by the technique employed. However, the heterogeneity of
the primary tumours could also potentially explain this
discordant result as it is possible that a biopsy did not
contain all mutant subclones (Fig. 1). Moreover, cfDNA
could also be shed from metastatic disease sites and het-
erogeneity between primary and metastatic tumours should
also be taken into consideration in interpreting the results
of the study.
Colorectal cancer
The genetic basic of colorectal cancer is well characterized
and importance of genetic biomarkers has been recognized
since late 1990s. Mutations in tumour suppressor genes,
APC and p53, and proto-oncogene, KRAS, are all impli-
cated in colorectal carcinogenesis. KRAS mutations are
detected in up to 40% of colorectal cancers (CRC) (Bos
et al. 1987). In CRC, KRAS mutations confer resistance to
treatment with EGFR antibodies and only patients with
wild type KRAS tumours obtain benefit from these agents
(Van Cutsem et al. 2009; Bokemeyer et al. 2009). It is
therefore vital that the KRAS mutation status of a patient’s
colorectal tumour can be detected to allow patients access
to treatment to which there is increased likelihood of
benefit.
Several studies have tried to establish the presence of
somatic mutations in cfDNA from patients with CRC.
Although there is a wide variation in techniques employed,
earlier studies have demonstrated; (1) cfDNA can be
detected in plasma of CRC patients and its level increases
with stage of disease (Diehl et al. 2005), (2) APC, p53 and
KRAS mutations can all be detected in cfDNA and could
serve as circulating biomarkers in CRC (Wang et al. 2004)
and (3) there is a potentially prognostic value of the
peresence of cfDNA in resected CRC during postoperative
follow up (Ryan et al. 2003). More recently, Diehl et al.
(2008) demonstrated that circulating mutant DNA can be
used to assess tumour dynamics in patients undergoing
multimodality therapies for CRC. Although increasing
clinical relevance of BRAF and PIK3CA mutations in CRC
is currently being recognized (Di Nicolantonio et al. 2008;
Sartore-Bianchi et al. 2009; Perrone et al. 2009), there is no
study reporting significance of detecting BRAF and
PIK3CA mutations in plasma or serum in CRC patients.
Pancreatic cancer
Although mutation in codon 12 of KRAS is a very common
event, occurring in up to 90% of pancreatic cancers, its
biological relevance in anticancer drug treatment resistance
is still not completely clear. However, considering the
scarcity of tumour materials for research in metastatic
pancreatic cancer, circulating biomarkers might be able to
help elucidate its biology. Preliminary studies demon-
strated the feasibility of detecting KRAS mutations in
plasma or serum of pancreatic cancer patients (Fle-
ischhacker and Schmidt 2007). Only three important
studies, which reflect the current status of cfDNA testing in
pancreatic cancer, will be discussed in this review. Castells
et al. (1999) studied KRAS mutations in 44 consecutive
patients with histologically confirmed primary pancreatic
ductal carcinoma using PCR–RFLP in both primary
tumours and plasma samples. A control group of 37
patients with chronic pancreatitis was also included in the
study. Out of 39 patients in whom both plasma and tissue
samples were available, 28 patients (72%) had KRAS
mutations in their primary tumours and 9 (23%) had
mutations detectable in plasma. Intriguingly, presence of
KRAS mutations in plasma was identified as the only
independent predictive factor of survival. However, plasma
KRAS mutation was also detected in two patients with
14 HUGO J (2010) 4:11–21
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chronic pancreatitis. Dianxu et al. (2002) tried to establish
the diagnostic value of codon 12 KRAS mutations in
plasma combined with serum CA19-9 in 58 consecutive
patients with a suspected pancreatic mass. Forty-one
patients were subsequently diagnosed with pancreatic
adenocarcinoma. Mutations in KRAS codon 12 were found
in 29 (71%) patients in plasma using PCR–RFLP whereas
elevated CA19-9 was found in 30 patients with pancreatic
adenocarcinoma demonstrating that plasma KRAS mutation
does not have an advantage over CA 19-9 as a diagnostic
marker in this setting. Perhaps more encouragingly, cir-
culating KRAS codon 12 mutations could serve as predic-
tive biomarkers in locally advanced pancreatic cancer
patients undergoing combined modalities treatment with
chemo-radiotherapy and gefitinib in a phase I study (Olsen
et al. 2009). KRAS mutations were detected in 5 of 11
patients enrolled in the pre-gefitinib plasma; of those five
patients, KRAS mutations became undetectable post ther-
apy in three patients and had overall survival of 8, 11, and
21 months. In contrast, two patients whose post-treatment
plasma still had mutant KRAS survived only 2 and
4 months. This study demonstrated that incorporating
KRAS status into early phase trials using currently available
techniques could produce potentially useful information.
Breast cancer
Somatic PIK3CA mutations occur in *25% of breast
cancer (Bachman et al. 2004; Lee et al. 2005; Levine et al.
2005). As such, mutated PI3K has become an attractive
therapeutic target in breast cancer therapy and a number of
agents targeting the PIK pathway are currently in clinical
development. Parallel with this development, our group
demonstrated the feasibility of PIK3CA testing in cfDNA.
CfDNA was extracted from plasma and serum samples of
46 patients and four hot spot mutations in PIK3CA gene,
p.H1047R, p.H1047L, p.E545K and p.E542K, were ana-
lyzed with Scorpion-ARMS. Matched tumour and plasma
data was available for 41 cases. Ten (24%) mutations were
detected in tumour and of those ten patients, 8 (80%) had
mutations in cfDNA isolated from plasma and 6 (60%) had
mutations in cfDNA isolated from serum. Concordance
between matched tumour and cell free DNA data was 95%
(95%CI: 83–99%) and 88% (95% CI: 73–95%) for plasma
derived cfDNA and serum derived cfDNA respectively.
Chen et al. (2009) demonstrated in a proof of principle
study that tumour specific p53 mutations in plasma could
be used to monitor patients’ response to chemotherapy in
six patients with stage II and III breast cancer, who
underwent neo-adjuvant chemotherapy. Based on these
studies, a mutation signature in plasma would be a useful
predictive circulating biomarker in breast cancer and con-
firmation of these early results in lager studies are needed.
Cutaneous melanoma
In cutaneous melanoma, the BRAF gene is mutated in
*60% of cases and p.V600E (c.1799T [ A) accounts for
more than 90% of BRAF mutations (Brose et al. 2002). In
2007, two studies reported the feasibility of BRAF mutation
testing from cfDNA (Daniotti et al. 2007; Yancovitz et al.
2007). Shinozaki et al. (2007) were the first to assess the
value of BRAF mutations in serum derived cfDNA as a
pharmacodynamic marker to biochemotherapy. Forty-eight
patients with stage IV disease were included in the study.
Out of 24 responders, 10 (41%) had BRAF mutations in
serum before biochemotherapy detected by using a peptide
nucleic acid (PNA) clamp and locked nucleic acid (LNA)
mediated quantitative real time PCR. In 9 of those 10
patients, BRAF mutations was no longer detectable in
serum within 4 weeks of the last cycle of treatment dem-
onstrating potential value of circulating BRAF mutations in
treatment response monitoring in metastatic cutaneous
melanoma; presence of BRAF mutations in serum was
associated with significantly worse overall survival in
patients receiving biochemotherapy.
Our group investigated the clinical utility of cfDNA
from serum as an alternative source of BRAF mutation
testing in 126 metastatic melanoma patients who partici-
pated in a phase II study testing the efficacy of AZD6244, a
specific MEK1/2 inhibitor (Board et al. 2009). Responses
to AZD6244 were observed only in patients whose tumours
harboured BRAF mutations. ARMS was used for both
mutation testing in tumours and serum. Matched tumour
and serum samples were available in 96 cases and 45
(47%) patients have BRAF mutation in tumour and 25
(27%) patients have BRAF mutation in serum derived
cfDNA. Based on those data, concordance in BRAF
mutation detection was 76% (95% CI 66–84%) and pick up
rate in cfDNA was 56% (95% CI 40–70%). Further studies
include collection of cfDNA to optimize the use of BRAF
mutation analysis in cfDNA to preselect patients for
treatment with this targeted therapy. In a separate study,
absolute concentration of BRAF p.V600E mutant copies in
plasma distinguished patients with invasive melanomas
(n = 55) from healthy controls (n = 18) with 97% sensi-
tivity and 83% specificity and concordance between
mutations detected in plasma and those of tumour tissue
was 80% (Pinzani et al. 2010).
Thyroid cancer
The BRAF p.V600E mutation occurs in *40% of patients
with papillary thyroid carcinoma and is associated with a
more aggressive disease (Cohen et al. 2004; Xing et al.
2005). BRAF mutation can be detected in serum derived
DNA from patients with papillary thyroid carcinomas
HUGO J (2010) 4:11–21 15
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(Chuang et al. 2010) and further studies will be needed to
determine the clinical utility of mutation testing from
cfDNA in this patient group.
Hepatocellular carcinoma
Mutation in TP53 is implicated in pathogenesis of HCC
(Hussain et al. 2007). It occurs in more than 50% of
patients with HCC from high incidence areas such as sub-
Saharan Africa and East Asia (Hainaut and Hollstein 2000)
and Ser-249 TP53 mutation, a missense mutation resulting
in substitution of arginine with serine at codon 249, reflects
high dietary exposure to aflatoxins (Hsu et al. 1991). A few
studies reported the feasibility of detection of Ser-249
mutation in cfDNA derived from plasma or serum of HCC
patients (Szyman´ska et al. 2004; Kirk et al. 2005; Hosny
et al. 2008) highlighting the potential role of using circu-
lating mutant DNA in diagnosis of HCC.
Recent studies that investigated the concordance
between somatic mutations detected in cfDNA and those
detected from tumours and early exploratory studies that
tested the pharmacodynamic value of circulating mutant
DNA in patients with cancer are summarized in Tables 1
and 2 respectively.
Novel techniques for mutation testing from cf DNA
Currently, Sanger sequencing is the most widely used
technique for screening of somatic mutations in solid
tumours. However, this can detect a mutation of interest
only when a sample contains 15–20% of mutant alleles
(Tsiatis et al. 2010). In contrast, pyrosequencing, which is a
more sensitive sequencing platform, detects down to 5% of
mutant alleles (Tsiatis et al. 2010). ARMS-Scorpion PCR
assay offers better sensitivity with an ability to detect the
presence of a mutant at 1% of the total DNA (Board et al.
2008), albeit with a substantial extra financial cost. How-
ever, as well as tumour derived mutant DNA, wild type
DNA also circulates in the blood and the tumour derived
mutant DNA fraction in cfDNA could be significantly less
than 1% (Diehl et al. 2005; Angenendt et al. 2010). This
imposes a difficult technical challenge in developing a
sensitive cfDNA assay for mutation detection. As sum-
marised in Table 1, for most tumour types, sensitivity
remains the major issue for currently available cfDNA
assays and implementation of novel technology platforms
will be necessary to improve the clinical utility of somatic
mutation detection from cfDNA. This review will outline
newer technology platforms that may offer advantages over
currently available techniques and could improve mutation
detection in cfDNA.
Microfluidic digital PCR (Biomark System)
This technique was first used by Yung et al. (2009) in
detection of EGFR mutations in plasma derived cfDNA of
patients with NSCLC. A major advantage of this technique
over other PCR based techniques is that mutant copy num-
bers can also be counted. The Biomark Digital Array Chip
Table 1 Summary of cfDNA studies that investigated the concordance between mutations detected in cfDNA and matched tumour






















Kimura et al. (2007) 42 Scorpion-ARMS Serum 19% 21.4% 92.9
Maheswaran et al.
(2008)
12a Scorpion-ARMS Plasma N/A N/A 33
Rosell et al. (2009) 164a PNA mediated
PCR
Serum N/A N/A 59
KRAS Wang et al. (2010) 273 PCR–RFLP Plasma 12.8% 11% 76.7
Pancreatic cancer KRAS Castells et al. (1999) 39 PCR–RFLP Plasma 23% 72% 32
Breast cancer PIK3CA Board et al. (2010) 41 Scorpion-ARMS Plasma 19.5% 24% 95
Angenendt et al.
(2010)
50 BEAMing Plasma 30% 30% 100
Cutaneous
melanoma
BRAF Board et al. (2009) 96 ARMS Serum 26.6% 47% 76
Pinzani et al. (2010) 56 Allele specific
real time PCR
Plasma 42% 51% 80
ARMS amplification refractory mutation testing system, EGFR epidermal growth factor receptor, PNA protein nucleic acid, RFLP restriction
fragment length polymorphism, BEAMing beads, emulsions, amplification and magnetics, NA not applicable
a All patients had EGFR mutations in tumour
16 HUGO J (2010) 4:11–21
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consists of twelve panels with each panel further partitioned
into 765 reaction chambers. One chip can perform 9180
reactions in a single run. PCR reactions from each chamber
yield a fluorescent signal and the colour of the signal depends
on whether there is any mutant copy in the chamber. By
counting different color coded signals from reaction wells, it
is possible to count mutant and wild type copies contained in
a sample. This technique could detect one mutant copy in the
background of 1,000 wild type copies. The results from Yung
et al., in a small study, are superior to those seen previously
with ARMS and other technologies. Furthermore, the
quantification of mutant sequences possible with this tech-
nique allowed demonstration of reduced mutant sequences in
those patients with partial or complete responses to EGFR
inhibitors and raises the possibility of developing cfDNA as a
pharmacodynamic biomarker.
BEAMing (beads, emulsion, amplifications
and magnetics)
BEAMing is a novel, highly sensitive PCR based technique
for DNA mutation detection (Diehl et al. 2006). PCR
products are amplified and tagged before being attached to
beads during a water-in-oil emulsion step. A single base
extension at the position of the mutation is performed on
the beads to label mutant and wild type beads with different
fluorescence. The beads are analysed by flow cytometry
and sequencing can be performed from single beads to
confirm the presence of wild type or mutant sequences.
This technique is reported to be able to detect a single
mutant sequence in 10,000 wild type sequences (Li et al.
2006). Using this technology mutant APC sequences can be
detected in cfDNA from patients with CRC, with an
average of 11% (1.9–27.0%) mutant sequences in patients
with advanced (Dukes D) CRC compared to 0.9%
(0.03–1.75%) mutant sequences in Dukes B CRC (Diehl
et al. 2005). This technique has been applied subsequently
to cfDNA from patients undergoing chemotherapy and
surgery for CRC and has demonstrated that sequential
measurement of mutant DNA fragments in plasma can be
used as an indicator of disease response or relapse (Diehl
et al. 2008). The major disadvantage of this technology for
using in the disease monitoring is that a specific marker
assay has to be developed for each patient and tumour
biopsy is required to screen for markers in order to do this.
This restricts the use of BEAMing to cases where tumour
biopsies are available or where BEAMing is used to
monitor disease post surgery. It is not currently suitable for
screening asymptomatic individuals for cancer where the
specific DNA alteration is unknown. However, a major
advantage of this technique is its sensitivity and one recent
study reported that in a cohort of 50 metastatic breast
cancer patients, PIK3CA mutations could be tested reliably
from plasma derived cfDNA by using BEAMing with
concordance between mutations detected from plasma and
tumour of 100% (Angenendt et al. 2010).
Next generation sequencing
The advent of massively parallel DNA sequencing platforms
has changed the landscape of cancer genomic research.
Currently, there are three next generation platforms, Roche
454 Genome Sequencer FLX Titanium, Illumina Genome
Analyzer II and ABI SOLiD. These technologies have
Table 2 Summary of exploratory studies that tested pharmacodynamic value of ctDNA












ctDNA reflects the tumour burden
ctDNA is more reliable and sensitive indicator









KRAS Five patients had ctDNA in pretreatment plasma
Of those five patients, ctDNA became undetectable in 3 patients















48 (stage IV) Bio-
chemotherapy
BRAF Twenty-four patients responded to treatment
Ten responders had ctDNA in pretreatment serum and nine of
those had undetectable ctDNA in serum within 4 weeks
of the last cycle of treatment
BRAF mutation in serum is associated with
significantly worse overall survival
ctDNA circulating mutant DNA, CEA carcino-embryonic antigen
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effectively been used for whole cancer genome sequencing
for analysis of single nucleotide variants, whole genome
analysis of somatic rearrangements and whole transcriptome
sequencing (Shah et al. 2009; Pleasance et al. 2009; Maher
et al. 2009). Leary et al. (2010) have recently demonstrated
that a specific somatic rearrangement signature could be
found in cancer patients using massively parallel sequencing
and these signatures could be detected in patients’ plasma by
using digital PCR approach. Van der Vaart et al. (2009) also
reported characterisation of cfDNA from 12 prostate cancer
patients and 10 healthy controls by parallel tagged
sequencing on the 454 platform.
With the exception of the few small studies outlined
above, these technologies have yet to be applied in large-
scale trials of cfDNA. The main drawback to these plat-
forms is that they work optimally with non-degraded,
micromolar input of DNA which is not a characteristic of
cfDNA. The sensitivity of these technologies is yet to be
established but will ultimately be dependant upon the DNA
input (for example, a sensitivity of less than 0.1% is the-
oretically impossible if less than 1,000 template copies are
available). A pre-amplification step can be used prior to
sequencing but whole genome amplification of cfDNA in
cancer may not be representative of the initial DNA tem-
plate. Despite these caveats, with further technological
advances, next generation sequencing platforms are likely
to be increasingly applied to cfDNA and could revolu-
tionise cancer molecular genetics.
Conclusion
Since the discovery of circulating nucleic acids in human
by Mandel and Metais in 1948, circulating or cell free
DNA research has progressed to the point where intro-
duction into routine clinical practice is a real possibility.
The main challenge remains to make cancer genomic data
applicable to the management of cancer patients and testing
genetic biomarkers more accessible in a minimally inva-
sive way. This tremendous challenge will require concerted
efforts of cancer genomic researchers, translational
research community and cancer physicians. Well designed
translational research studies are urgently needed for
qualification of genetic biomarkers which are already
available from recent studies of whole genome sequencing
of cancer. From this perspective, looking into cancer
genomic landscapes through the windows of cfDNA
analysis is an exciting prospect.
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